Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer
Measuring both tumor cells and immune markers in blood together may better predict how metastatic breast cancer patients will respond to treatment.
This prospective study characterized immune status and protein profiles in relation to CTC burden in metastatic breast cancer, revealing clinically relevant correlations between liquid biopsy components and treatment outcomes. The integration of CTCs with immune profiling represents an emerging multi-analyte liquid biopsy approach with potential for monitoring and treatment guidance.
What the study was
- Study design
- Prospective clinical study (ALCINA 2 trial, ethics committee-approved)
- Population
- Patients with metastatic breast cancer
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Journal of Experimental and Clinical Cancer Research
Why it surfaced
Multi-analyte liquid biopsy (CTC + immune + proteomics) in metastatic BC is a high-interest area; prospective design with ethics approval adds credibility; full abstract not retrieved so classification is medium confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.